EP0257956B2
(en)
*
|
1986-08-19 |
2000-11-22 |
Genentech, Inc. |
Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
|
US5766897A
(en)
*
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
US6582728B1
(en)
*
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
US5661125A
(en)
*
|
1992-08-06 |
1997-08-26 |
Amgen, Inc. |
Stable and preserved erythropoietin compositions
|
US6012450A
(en)
*
|
1993-01-29 |
2000-01-11 |
Aradigm Corporation |
Intrapulmonary delivery of hematopoietic drug
|
US6051256A
(en)
*
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
PT748213E
(pt)
|
1994-03-07 |
2004-08-31 |
Nektar Therapeutics |
Metodos e composicoes para administracao pulmonar de insulina
|
ATE299892T1
(de)
|
1994-05-18 |
2005-08-15 |
Nektar Therapeutics |
Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
|
US6290991B1
(en)
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
US6586006B2
(en)
|
1994-08-04 |
2003-07-01 |
Elan Drug Delivery Limited |
Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
|
IL116085A
(en)
*
|
1994-12-16 |
1999-12-31 |
Ortho Pharma Corp |
Spray dried erythropoietin
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
CA2216443A1
(en)
*
|
1995-03-31 |
1996-10-03 |
Aradigm Corporation |
Intrapulmonary delivery of hematopoietic drug
|
JP3708553B2
(ja)
*
|
1995-04-14 |
2005-10-19 |
ネクター セラピューティクス |
向上した分散性を有する粉末型薬理組成物
|
EP2055712A1
(en)
|
1995-06-07 |
2009-05-06 |
Glaxo Group Limited |
Peptides and compounds that bind to a thrombopoietin receptor
|
US5869451A
(en)
|
1995-06-07 |
1999-02-09 |
Glaxo Group Limited |
Peptides and compounds that bind to a receptor
|
DE19539574A1
(de)
*
|
1995-10-25 |
1997-04-30 |
Boehringer Mannheim Gmbh |
Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
|
US5875776A
(en)
*
|
1996-04-09 |
1999-03-02 |
Vivorx Pharmaceuticals, Inc. |
Dry powder inhaler
|
ATE247948T1
(de)
*
|
1996-04-29 |
2003-09-15 |
Dura Pharma Inc |
Verfahren zum inhalieren trockener pulver
|
US7091311B2
(en)
|
1996-06-07 |
2006-08-15 |
Smithkline Beecham Corporation |
Peptides and compounds that bind to a receptor
|
GB9612297D0
(en)
*
|
1996-06-11 |
1996-08-14 |
Minnesota Mining & Mfg |
Medicinal aerosol formulations
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
DE19733651A1
(de)
*
|
1997-08-04 |
1999-02-18 |
Boehringer Ingelheim Pharma |
Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
DE69814428T2
(de)
†
|
1997-09-29 |
2004-05-13 |
Nektar Therapeutics, San Carlos |
In verneblern verwendbare, stabilisierte zubereitungen
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
JP2002512039A
(ja)
|
1998-04-22 |
2002-04-23 |
コーネル リサーチ ファンデーション インク. |
イヌエリスロポエチン遺伝子および組換えタンパク質
|
MXPA01011429A
(es)
*
|
1999-05-11 |
2003-09-10 |
Ortho Mcneil Pharm Inc |
Modelado farmacocinetico y farmacodinamico de administracion de eritropoyetina.
|
US20030190644A1
(en)
|
1999-10-13 |
2003-10-09 |
Andreas Braun |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
ATE364689T1
(de)
|
1999-11-18 |
2007-07-15 |
Dendreon Corp |
Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
|
SK11142002A3
(sk)
*
|
1999-12-30 |
2004-09-08 |
Chiron Corporation |
Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
TWI290473B
(en)
|
2000-05-10 |
2007-12-01 |
Alliance Pharma |
Phospholipid-based powders for drug delivery
|
ATE291436T2
(de)
*
|
2000-05-15 |
2005-04-15 |
Hoffmann La Roche |
Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
|
US7575761B2
(en)
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
GB0027357D0
(en)
*
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
ATE420630T1
(de)
*
|
2000-11-29 |
2009-01-15 |
Itoham Foods Inc |
Pulverzubereitungen und verfahren zu ihrer herstellung
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
NZ548578A
(en)
*
|
2001-02-02 |
2008-03-28 |
Ortho Mcneil Pharm Inc |
Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
|
US20030072717A1
(en)
*
|
2001-02-23 |
2003-04-17 |
Vapotronics, Inc. |
Inhalation device having an optimized air flow path
|
WO2002072786A2
(en)
|
2001-03-13 |
2002-09-19 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
GB0107106D0
(en)
*
|
2001-03-21 |
2001-05-09 |
Boehringer Ingelheim Pharma |
Powder inhaler formulations
|
KR20040011480A
(ko)
|
2001-03-22 |
2004-02-05 |
덴드레온 샌 디에고 엘엘씨 |
세린 프로테아제 cvsp14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
|
ES2268044T3
(es)
*
|
2001-05-21 |
2007-03-16 |
Injet Digital Aerosols Limited |
Composiciones para la administracion de proteinas por la via pulmonar.
|
EG24184A
(en)
*
|
2001-06-15 |
2008-10-08 |
Otsuka Pharma Co Ltd |
Dry powder inhalation system for transpulmonary
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
PT1458360E
(pt)
|
2001-12-19 |
2011-07-13 |
Novartis Ag |
Derivados de indole como agonistas do recetor s1p1
|
AU2002351746A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Maxygen Aps |
Erythropoietin conjugates
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
AU2003228809A1
(en)
|
2002-05-03 |
2003-11-17 |
Sequenom, Inc. |
Kinase anchor protein muteins, peptides thereof, and related methods
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
US20040009908A1
(en)
*
|
2002-07-10 |
2004-01-15 |
Stamler Jonathan S. |
Methods for treating or preventing ischemic injury
|
DE10234165B4
(de)
*
|
2002-07-26 |
2008-01-03 |
Advanced Micro Devices, Inc., Sunnyvale |
Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
MXPA05003057A
(es)
|
2002-09-18 |
2006-04-18 |
Johnson & Johnson |
Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
|
EP1852441B1
(en)
|
2002-09-24 |
2012-03-28 |
The Burnham Institute |
Agents that modulate EPH receptor activity
|
WO2004047768A2
(en)
*
|
2002-11-26 |
2004-06-10 |
Seacoast Neuroscience, Inc. |
Buoyant polymer particles delivering therapeutic agents
|
US20040132645A1
(en)
*
|
2003-01-03 |
2004-07-08 |
Knox Susan J. |
Methods for modulating effects of radiation in a subject
|
WO2004073623A2
(en)
|
2003-02-14 |
2004-09-02 |
Children's Hospital & Research Center At Oakland |
Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
|
CA2521979A1
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
DE102004004509B4
(de)
*
|
2004-01-23 |
2010-07-01 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
EP1848461A2
(en)
*
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
US7927787B2
(en)
|
2006-06-28 |
2011-04-19 |
The Invention Science Fund I, Llc |
Methods and systems for analysis of nutraceutical associated components
|
US20080210748A1
(en)
|
2005-11-30 |
2008-09-04 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware, |
Systems and methods for receiving pathogen related information and responding
|
US8000981B2
(en)
|
2005-11-30 |
2011-08-16 |
The Invention Science Fund I, Llc |
Methods and systems related to receiving nutraceutical associated information
|
US8340944B2
(en)
|
2005-11-30 |
2012-12-25 |
The Invention Science Fund I, Llc |
Computational and/or control systems and methods related to nutraceutical agent selection and dosing
|
US7827042B2
(en)
|
2005-11-30 |
2010-11-02 |
The Invention Science Fund I, Inc |
Methods and systems related to transmission of nutraceutical associated information
|
US10296720B2
(en)
|
2005-11-30 |
2019-05-21 |
Gearbox Llc |
Computational systems and methods related to nutraceuticals
|
US8297028B2
(en)
|
2006-06-14 |
2012-10-30 |
The Invention Science Fund I, Llc |
Individualized pharmaceutical selection and packaging
|
US7974856B2
(en)
|
2005-11-30 |
2011-07-05 |
The Invention Science Fund I, Llc |
Computational systems and methods related to nutraceuticals
|
TW200810773A
(en)
*
|
2006-04-19 |
2008-03-01 |
Alba Therapeutics Corp |
Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
|
KR101476458B1
(ko)
|
2006-07-05 |
2015-01-05 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
US8148377B2
(en)
|
2007-02-11 |
2012-04-03 |
Map Pharmaceuticals, Inc. |
Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
|
TW201803586A
(zh)
|
2008-08-14 |
2018-02-01 |
艾瑟勒朗法瑪公司 |
使用gdf阱以增加紅血球水平
|
CA2767773C
(en)
|
2011-02-11 |
2015-11-24 |
Grain Processing Corporation |
Composition comprising a salt and a crystallization interrupter
|
EP3875104A1
(en)
*
|
2011-10-17 |
2021-09-08 |
Acceleron Pharma Inc. |
Compositions for treating myelofibrosis
|
CA2861392C
(en)
|
2012-01-26 |
2021-08-17 |
Christopher J. Soares |
Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
WO2015136527A1
(en)
|
2014-03-10 |
2015-09-17 |
Health Corporation - Rambam |
Heparanase inhibitory peptides and use thereof for treating clinical pathologies
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
ES2965087T3
(es)
|
2016-09-02 |
2024-04-10 |
Soares Christopher J |
Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
|
EP3658191A1
(en)
|
2017-07-26 |
2020-06-03 |
Janssen Pharmaceutica NV |
Methods of protecting vascular integrity induced by targeted radiation therapy
|
KR20210119469A
(ko)
|
2019-01-25 |
2021-10-05 |
잔센파마슈티카엔.브이. |
전신 방사선/화학 노출에 대응한 장기 및 혈관 손상에 대한 보호, 조혈 회복 및 생존을 증진시키는 방법
|
WO2020209920A2
(en)
|
2019-01-25 |
2020-10-15 |
Janssen Pharmaceutica Nv |
Methods of mitigating toxic effects of vesicants and caustic gas
|
MA54820A
(fr)
|
2019-01-25 |
2021-12-01 |
Janssen Pharmaceutica Nv |
Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
|
WO2020201038A1
(en)
|
2019-03-29 |
2020-10-08 |
Pieris Pharmaceuticals Gmbh |
Inhaled administration of lipocalin muteins
|
BR112022001185A2
(pt)
|
2019-08-01 |
2022-03-15 |
Acm Biolabs Pte Ltd |
Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
|
WO2021214339A2
(en)
|
2020-04-24 |
2021-10-28 |
Acm Biolabs Pte Ltd |
Vaccine against human-pathogenic coronaviruses
|
US20230398207A1
(en)
|
2020-12-11 |
2023-12-14 |
Acm Biolabs Pte Ltd |
Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
|
AU2022216818A1
(en)
|
2021-02-02 |
2023-07-27 |
Acm Biolabs Pte Ltd |
Sole use of polymersome associated adjuvant for stimulating an immune response
|
KR20230165917A
(ko)
|
2021-04-08 |
2023-12-05 |
피어이스 파마슈티컬즈 게엠베하 |
결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인
|
US20230104658A1
(en)
|
2021-10-01 |
2023-04-06 |
Janssen Pharmaceutica Nv |
Methods of increasing progenitor cell production
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|